Scope
NICE guideline NG88 covers assessing and managing heavy menstrual bleeding (HMB) in women. It addresses history, examination and blood tests; when and how to investigate structural causes, including hysteroscopy and ultrasound; counselling on treatments and fertility; and management by findings. These groups are women with no identified pathology, fibroids under 3 cm or adenomyosis, and women with fibroids of 3 cm or more. Surgical guidance covers endometrial ablation, uterine artery embolisation, myomectomy and hysterectomy. Recommendation strength is kept as worded: 'consider' items are options, while 'offer' and 'do not' items are firmer. Interventions should aim to improve quality of life rather than focus on blood loss.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
History, examination and blood tests
- Treatment goals should centre on the woman's quality of life, not measured blood loss. The history should cover bleeding pattern and quality-of-life impact. It should note symptoms such as persistent intermenstrual bleeding, pelvic pain or pressure that point to cavity or histological abnormality, adenomyosis or fibroids. It should also cover comorbidities and prior HMB treatment. [1]
- If HMB occurs without related symptoms, drug treatment may be considered without a physical examination, unless an LNG-IUS is chosen. Offer examination when related symptoms are present. Always examine before any investigation or LNG-IUS fitting. [1]
- Check a full blood count in every woman with HMB, alongside any treatment. Consider coagulation testing, for example for von Willebrand's disease, if HMB has been present since periods began and personal or family history suggests a coagulation disorder. Do not test female hormones. Test thyroid hormones only if other features of thyroid disease are present. [1]
Investigating the cause
- When history and examination suggest a low risk of fibroids, cavity or histological abnormality, or adenomyosis, drug treatment can be considered without investigation. If cancer is suspected, use the separate NICE suspected-cancer referral guideline. [1]
- Offer outpatient hysteroscopy when the history suggests submucosal fibroids, polyps or endometrial pathology. This applies to symptoms such as persistent intermenstrual bleeding, or to risk factors for endometrial pathology. If the woman declines outpatient hysteroscopy, offer it under general or regional anaesthesia. If she declines hysteroscopy altogether, consider pelvic ultrasound and explain its limitations for detecting cavity causes. [1]
- Consider endometrial biopsy during hysteroscopy for women at high risk of endometrial pathology. Examples include persistent intermenstrual or irregular bleeding, and infrequent heavy bleeding with obesity or polycystic ovary syndrome. They also include tamoxifen use and failed HMB treatment. Sample the endometrium only during diagnostic hysteroscopy; do not offer blind biopsy. [1]
- Offer pelvic ultrasound if the uterus is palpable abdominally, a pelvic mass is suggested, or examination is inconclusive or difficult, for example with obesity. [1]
- For significant dysmenorrhoea or a bulky, tender uterus suggesting adenomyosis, offer transvaginal ultrasound in preference to transabdominal ultrasound or MRI. If transvaginal scanning is declined or unsuitable, consider transabdominal ultrasound or MRI and explain their limitations. Remember that pain may reflect endometriosis rather than adenomyosis. [1]
- Saline infusion sonography and MRI should not be used as first-line diagnostic tools. Dilatation and curettage alone should not be used for diagnosis. [1]
Counselling and fertility
- Discuss all treatment options, including benefits and risks, suitable choices if trying to conceive, and wishes to retain fertility or the uterus. Explain the fertility impact of planned surgery or embolisation, and allow discussion where hysterectomy or ablation would end fertility. Explain that embolisation or myomectomy may potentially preserve fertility. After ablation, advise avoiding pregnancy and using effective contraception if needed. [1]
- Before any decision on hysterectomy, discuss its implications fully. Topics include sexual feelings, bladder function and psychological impact. Also explain the higher risk of serious complications when fibroids are present. Warn about possible loss of ovarian function even if the ovaries are conserved. [1]
Management: no pathology, fibroids under 3 cm, or adenomyosis
- Consider an LNG-IUS as first treatment if no pathology is found, fibroids are less than 3 cm without cavity distortion, or adenomyosis is suspected or diagnosed. This is off-label for some devices. Warn about bleeding-pattern changes, especially in early cycles and possibly beyond 6 months. Advise waiting at least 6 cycles to judge benefit. [1]
- If an LNG-IUS is declined or unsuitable, consider tranexamic acid, NSAIDs, combined hormonal contraception or cyclical oral progestogens. NSAIDs and some combined hormonal contraceptives are off-label. Progestogen-only contraception may suppress menstruation, which could help. [1]
- Consider specialist referral if treatment fails, drug treatment is declined, or symptoms are severe. Referral allows further investigation, accounting for previous tests. It also allows untried drugs or surgery, such as second-generation endometrial ablation or hysterectomy. [1]
- For submucosal fibroids, hysteroscopic removal may be considered. [1]
Management: fibroids 3 cm or more
- Consider specialist referral for further investigation and treatment discussion. If drug treatment is needed meanwhile, offer tranexamic acid and/or NSAIDs. Continue them for as long as they help. [1]
- Choose among options while weighing fibroid size, location and number and symptom severity. Options include drugs such as tranexamic acid, NSAIDs or an LNG-IUS, uterine artery embolisation, or surgery including hysterectomy. Drug effectiveness may be limited when fibroids are substantially greater than 3 cm. [1]
- If treatment fails, consider reinvestigating the cause, accounting for earlier results. Offer an alternative from the listed fibroid options. [1]
- Ulipristal acetate is limited to intermittent treatment of moderate to severe fibroid symptoms in premenopausal women, and only when surgery and embolisation are unsuitable, have failed or are declined. [1]
- Warn about serious liver injury and liver failure with ulipristal acetate. Check liver function before starting and monthly for the first 2 courses. Also check before each new course when clinically indicated. If there is no underlying liver injury and surgery and embolisation are unsuitable or have failed, consider 5 mg for up to 4 courses in premenopausal women with HMB and fibroids of 3 cm or more, particularly if haemoglobin is 102 g per litre or below. Stop the drug and test liver function urgently if signs and symptoms of liver failure appear. [1]
- Second-generation endometrial ablation may be considered for fibroids of 3 cm or more if the device manufacturer's criteria are met. [1]
- Before scheduling embolisation or myomectomy, assess the uterus and fibroids by ultrasound. Consider MRI if more detail on fibroid position, size, number or vascularity is needed. Consider GnRH-analogue pretreatment before hysterectomy or myomectomy when fibroids enlarge or distort the uterus. [1]
Hysterectomy and procedural safeguards
- Individualise the hysterectomy route with the woman's preferences, and discuss total versus subtotal hysterectomy. Remove ovaries only at her express wish, with informed consent after discussing risks and benefits. [1]
- Do not offer dilatation and curettage as treatment. If dilatation is needed for non-hysteroscopic ablation, exclude perforation or false passage first. Perform hysteroscopy before inserting the device. Ultrasound may confirm placement, with any balloon kept inflated during scanning. [1]
Limitations and use
- Only the recommendations chapter was reviewed; research recommendations, rationale/impact and evidence reviews were not included.
- Flowcharts and visual algorithms were available only as alternative text.
- Details of GnRH antagonists (linzagolix, relugolix combination therapy) and thermal balloon/microwave ablation are deferred to separate NICE technology appraisals and are not summarised here.
- Suspected cancer and endometriosis are covered by other NICE guidelines referenced by this guidance.
- Outpatient hysteroscopy service-organisation recommendations (analgesia, vaginoscopy, see-and-treat) are not itemised in this summary.
- Several drug uses are off-label (some LNG-IUSs, NSAIDs, some combined hormonal contraceptives, some GnRH analogues).
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Heavy menstrual bleeding: assessment and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 14 March 2018
- Publisher’s latest update
- 7 July 2026
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.